Perspectives on the pharmacological management of esophageal cancer: where are we now and where do we need to go?-Reference-Cited by-同舟云学术

Perspectives on the pharmacological management of esophageal cancer: where are we now and where do we need to go?

Published:2022-11-02 Issue:17 Volume:23 Page:1893-1902
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Rogers Jane E.¹,Ajani Jaffer A.²

Affiliation:

1. Department of Pharmacy Clinical Programs, U.T. M.D. Anderson Cancer Center Pharmacy Clinical Programs, Houston TX, USA

2. U.T. M. D. Anderson Cancer Center, Department of Gastrointestinal Medical Oncology, Houston, TX, USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2022.2140585

Reference87 articles.

1. National Comprehensive Cancer Network. Esophageal and Esophagogastric Junction Cancers. Version 2.2022; [cited 2022 Jun 20]. https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf.

2. U.S. Department of Health and Human Services. National cancer institute: surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: esophageal Cancer; [cited 2022 Jun 20]. https://seer.cancer.gov/statfacts/html/esoph.html

3. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

4. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

5. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DNA methylation markers in esophageal cancer;Frontiers in Genetics;2024-05-07